This site is intended for Healthcare professionals only.

Shilpa Medicare gets tentative USFDA nod for Multiple Sclerosis drug


Shilpa Medicare gets tentative USFDA nod for Multiple Sclerosis drug

New Delhi:  Shilpa Medicare has recently received tentative approval from the US health regulator for Dimethyl Fumarate delayed-release release capsules, used for the treatment of relapsing forms of multiple sclerosis.

Dimethyl Fumarate Delayed-Release Capsules 120 mg & 240 mg is a generic of Tecfidera used in the treatment of patients with relapsing forms of multiple sclerosis.

This ANDA is a first to file submission made on NCE-l dated March 27, 2017. FDA review process was completed and got approval within a period of 19.5 months from the date of submission.

According to IQVIA MAT Q2 2018 data, the US market for Dimethyl Fumarate DR Capsules is approximately US$ 3.46 billion.



Source: self
0 comment(s) on Shilpa Medicare gets tentative USFDA nod for Multiple Sclerosis drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted